CT-Guided ¹²⁵I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study

References

• Ferlay J , Colombet M , Soerjomataram I , et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer . 2019;144(8):1941–1953. doi:10.1002/ijc.31937 30350310
   PubMed Web of Science ®Google Scholar
• Zheng RS , Sun KX , Zhang SW , et al. Report of cancer epidemiology in China, 2015. Chin J Oncol . 2019;41(1):19–28.
   Google Scholar
• Zhou M , Wang H , Zeng X , et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1 31248666
   PubMed Web of Science ®Google Scholar
• Bray F , Ferlay J , Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: global cancer statistics 2018. CA Cancer J Clin . 2018;68(6):394–424. doi:10.3322/caac.21492 30207593
   PubMed Web of Science ®Google Scholar
• Ikeda M , Kudo M , Aikata H , et al. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a Phase III randomized trial. J Gastroenterol . 2018;53(2):281–290. doi:10.1007/s00535-017-1374-6 28766016
   PubMed Web of Science ®Google Scholar
• Yang JD , Heimbach JK . New advances in the diagnosis and management of hepatocellular carcinoma. BMJ . 2020;371:m3544. doi:10.1136/bmj.m3544 33106289
   PubMed Web of Science ®Google Scholar
• Kudo M , Matsui O , Izumi N , et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology . 2014;87(Suppl 1):22–31. doi:10.1159/000368142 25427730
   PubMed Web of Science ®Google Scholar
• Ernst O , Sergent G , Mizrahi D , et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumour response. Am J Roentgenol . 1999;172(1):59–64. doi:10.2214/ajr.172.1.9888740 9888740
   PubMed Web of Science ®Google Scholar
• Yu CX , Teng GJ . Transarterial chemoembolization refractory: current research progress. J Interv Radiol . 2017;26(12):1063–1067.
   Google Scholar
• Kokudo N , Hasegawa K , Akahane M , et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res . 2015;45(2):123–127. doi:10.1111/hepr.12464
   Web of Science ®Google Scholar
• Cheng AL , Kang YK , Chen ZD , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol . 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7 19095497
   PubMed Web of Science ®Google Scholar
• Llovet JM , Ricci S , Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med . 2008;359(4):378–390. doi:10.1056/NEJMoa0708857 18650514
   PubMed Web of Science ®Google Scholar
• Mendez-Blanco C , Fondevila F , García-Palomo A , et al. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med . 2018;50(10):1–9. doi:10.1038/s12276-018-0159-1
   PubMed Web of Science ®Google Scholar
• Rimassa L , Danesi R , Pressiani T , et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev . 2019;77:20–28. doi:10.1016/j.ctrv.2019.05.004 31195212
   PubMed Web of Science ®Google Scholar
• Hill A , Gotham D , Fortunak J , et al. Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open . 2016;6(1):e009586. doi:10.1136/bmjopen-2015-009586
   PubMed Web of Science ®Google Scholar
• Bae SH , Park HC , Lim DH , et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys . 2012;82(4):e603–607. doi:10.1016/j.ijrobp.2011.09.053 22208963
   PubMed Web of Science ®Google Scholar
• Dawson LA , Normolle D , Balter JM , et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys . 2002;53(4):810–821. doi:10.1016/S0360-3016(02)02846-8 12095546
   PubMed Web of Science ®Google Scholar
• Liang SX , Jiang GL , Zhu XD , et al. Radiation-induced liver disease: risk factors and liver irradiation tolerance. Oncol Prog . 2006;4(4):308–313.
   Google Scholar
• Zheng JP , Shao GL , Luo J , et al. CT-guided 125I seeds interstitial implantation for the refractory liver cancers ineffective to commonly used therapies. J Interv Radiol . 2015;24(3):260–264.
   Google Scholar
• Lv J , Cao XF , Zhu B . (125)I radioactive seeds implantation therapy for hepatocellular carcinoma. Gastroenterol Res . 2009;2(3):141–147. doi:10.4021/gr2009.05.1289
   PubMedGoogle Scholar
• Luo KY , Zheng JH , Li B , et al. Clinical application of iodine-125 seeds for hepatic carcinoma. J Hepatobiliary Surg . 2004;16(1):29–31.
   Google Scholar
• Ricke J , Wust P , Stohlmann A , et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: Phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys . 2004;58(5):1496–1505. doi:10.1016/j.ijrobp.2003.09.024 15050329
   PubMed Web of Science ®Google Scholar
• Chen L , Zheng CS . Application of 125I particle implantation combined with other therapies in treating liver cancers of different stages. J Interv Radiol . 2019;28(9):910–913.
   Google Scholar
• Song Z , Ye J , Wang Y , et al. Computed tomography-guided iodine-125 brachytherapy for unresectable hepatocellular carcinoma. J Cancer Res Ther . 2019;15(7):1553–1560. doi:10.4103/jcrt.JCRT_629_19 31939437
   PubMed Web of Science ®Google Scholar
• Lencioni R , Llovet JM . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis . 2010;30(1):52–60. doi:10.1055/s-0030-1247132 20175033
   PubMed Web of Science ®Google Scholar
• Idée JM , Guiu B . Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol . 2013;88(3):530–549. doi:10.1016/j.critrevonc.2013.07.003 23921081
   PubMed Web of Science ®Google Scholar
• Tak E , Lee S , Lee J , et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol . 2011;54(2):328–339. doi:10.1016/j.jhep.2010.06.045 21056497
   PubMed Web of Science ®Google Scholar
• Li X , Feng GS , Zheng CS , et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol . 2004;10(19):2878–2882. doi:10.3748/wjg.v10.i19.2878 15334691
   PubMed Web of Science ®Google Scholar
• Wang B , Xu H , Gao ZQ , et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol . 2008;49(5):523–529. doi:10.1080/02841850801958890 18568538
   PubMed Web of Science ®Google Scholar
• Kajihara J , Tomimaru Y , Eguchi H , et al. The clinical impact of transcatheter arterial chemoembolization (TACE)-induced c-met upregulation on TACE refractoriness in hepatocellular carcinoma. Dig Dis Sci . 2016;61(6):1572–1581. doi:10.1007/s10620-015-4018-9 26725068
   PubMed Web of Science ®Google Scholar
• Zeng ZC , Tang ZY , Fan J , et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J . 2004;10(5):307–316. doi:10.1097/00130404-200409000-00008 15530260
   PubMed Web of Science ®Google Scholar
• Zeng ZC , Tang ZY , Fan J , et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys . 2005;63(4):1067–1076. doi:10.1016/j.ijrobp.2005.03.058 15913915
   PubMed Web of Science ®Google Scholar
• Xu ZY , Liang SX , Zhu J , et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys . 2006;65(1):189–195. doi:10.1016/j.ijrobp.2005.11.034 16542787
   PubMed Web of Science ®Google Scholar
• Cao GW , Du MM , Cui XJ , et al. Efficacy of TACE combined with 125I radioactive particle implantation in the treatment of paracardiac hepatic carcinoma. Shandong Med . 2017;57(10):55–57.
   Google Scholar
• Lu X , Zeng GB , Lin LQ , et al. Transcatheter hepatic arterial oily chemoembolization combined with brightness mode guided125I seeds implantation for huge-type hepatoma. Chin Arch Gen Surg . 2014;8(2):125–129.
   Google Scholar
• Li WS , Liu FK , Chen ZH , et al. Changes of angiogenesis in rectal cancer patients after preoperative radiotherapy. Chin J Gen Surg . 2004;19(6):331–333.
   Google Scholar
• Tong WS , Pan JH , Qiu XL , et al. Influence of TACE combined with radioactive particle interstitial radiotherapy on malignant biological indexes in patients with primary hepatocellular carcinoma. Pract J Cancer . 2018;33(3):416–418.
   Google Scholar
• Guo Q , Li Y , Yan YM , et al. Efficacy of TACE combined with 125I radioactive particle implantation in the treatment of hepatic carcinoma. J Med Imaging . 2012;22(7):1130–1132.
   Google Scholar